Alexis Battle is an Associate Professor at Johns Hopkins University with appointments in Biomedical Engineering , Computer Science , and Genetic Medicine (secondary). She directs the Malone Center for Engineering in Healthcare and serves as Deputy Director of the Data Science and AI Institute . Educated at Stanford University (PhD in Computer Science, 2013), Battle transitioned to academia after leadership roles at Google. Research Focus: Battle’s work bridges genomics and machine learning , emphasizing the impact of genetic variation on human health. Her lab develops tools like Watershed to predict functional effects of rare variants, aiming to enhance rare disease diagnosis. Key themes include non-coding DNA analysis , personalized genomics , and systems biology , with applications in cardiovascular disease and neurodegenerative disorders . Publications & Awards: Over 60 peer-reviewed articles in journals like Nature , Science , and Genome Biology , with recent emphasis on single-cell transcriptomics , multiomics integration , and telomere biology . Recipient of the President’s Frontier Award (2022), Microsoft Investigator Fellowship (2019), and Searle Scholar (2016). Scientific Awards: 2022 President’s Frontier Award 2019 Microsoft Investigator Fellowship 2019 Johns Hopkins Discovery Award 2017 Johns Hopkins Catalyst Award 2016 Searle Scholar Advising & Funding: Mentors 11 PhD students, 3 undergraduates, and postdoctoral fellows. Her research is funded by NIH, Searle Scholars, and institutional grants. The Battle Lab collaborates on projects like the GTEx Consortium , focusing on gene regulation and clinical genomics .
Dr. Yi Shen is a Senior Lecturer at the School of Chemical and Biomolecular Engineering, The University of Sydney, and Chair of RACI Women in Chemistry. She is also affiliated with multiple research institutes including Sydney Institute of Agriculture, Sydney Southeast Asia Centre, The Centre for Drug Discovery Innovation, and The University of Sydney Nano Institute. PhD in Soft Materials from ETH Zurich Postdoctoral research at University of Cambridge and Harvard University Her research focuses on protein phase behavior and functional biomaterials development, utilizing soft matter approaches and microfluidic techniques to address challenges in neurodegenerative diseases, sustainable materials, and biomedical engineering. She has published extensively in top journals like Nature Nanotechnology and PNAS, with a particular emphasis on: Protein liquid-liquid phase separation mechanisms Biomaterials from protein nanofibrils Microfluidic manipulation of biological systems Biodegradable bioplastics development Shear force effects on biomolecular systems Pathological protein aggregation dynamics Key scientific achievements include: 2022 ARC DECRA Fellowship 2022 Sydney Nano Frontier award 2018 ETH Zurich Spark Award (for Fe delivery system invention) 2012 Princeton Grand Challenges Program 2 patents pending 2 Nature Nanotechnology cover articles As an educator, she coordinates CHNG2802 Chemical Engineering Modelling and Analysis, co-teaches CHNG3804 Biochemical Engineering and CHNG5605 Bio-products: Laboratory to Marketplace, and guest lectures across biomedical and nanotechnology programs. Her lab actively collaborates with institutions in Switzerland (ETH Zurich), UK (Cambridge), and US (Harvard, Princeton), focusing on transforming biomolecular understanding into real-world applications in health, industry, and environmental sustainability.
Nancy J. Brown, M.D., is the Jean and David W. Wallace Dean of the Yale School of Medicine and holds the C.N.H. Long Professorship in Internal Medicine. Previously, she served as Chair of Vanderbilt Department of Medicine and Physician-in-Chief of Vanderbilt University Medical Center (2010–2020). Her academic career spans over three decades, with leadership roles in clinical care, research, and medical education. Education: MD, Harvard University (1986) AB in Molecular Biophysics and Biochemistry, Yale College (1981) Internship and Residency in Medicine, Vanderbilt University (1989) Fellowship in Clinical Pharmacology, Vanderbilt University (1991) Chief Resident, Vanderbilt University (1992) Research Interests: Dr. Brown’s work focuses on the renin-angiotensin-aldosterone system’s role in cardiovascular disease, hypertension, and thrombosis. Her lab has elucidated mechanisms linking aldosterone, bradykinin, and ACE inhibitors to inflammation, fibrosis, and cardiovascular risk. Current studies explore neprilysin inhibitors in heart failure and incretin-based therapies’ cardiovascular effects. Key Contributions: Identified genetic variants and African ancestry as risk factors for ACE inhibitor-associated angioedema Developed Vanderbilt’s Master of Science in Clinical Investigation program (2000) Advocated for physician-scientist development through leadership roles in NIH councils and professional organizations Recognition: Recipient of the Harriet Dustan Award, August M. Watanabe Prize, and Robert H. Williams Distinguished Chair of Medicine. Elected to the National Academy of Medicine and American Academy of Arts & Sciences. Labs/Teams: Leads the Yale School of Medicine’s cardiovascular research initiatives, focusing on translational studies of RAAS pathways and drug mechanisms.
David N. Ku is the Lawrence P. Huang Endowed Chair for Engineering Entrepreneurship and Regents' Professor at Georgia Institute of Technology. He holds appointments in the School of Mechanical Engineering (Woodruff School) within the College of Engineering. His research focuses on biofluid mechanics, medical device innovation, and translational technology, with emphasis on thrombosis mechanisms and vascular diseases. Education: M.D. from Emory University (1984); Ph.D. and M.S. from Georgia Tech (1983, 1982); B.A. from Harvard University (1978). Research interests include unsteady fluid dynamics in vascular systems, nanoparticle medical devices for thrombosis prevention, and porous thrombus applications for hemostasis. His work bridges bioengineering with entrepreneurship, teaching product development at the Business School and collaborating with Emory University, Paris Tech-Mines, and ETH Zurich. Key awards include the American Institute for Medical and Biological Engineering Fellowship, DLA Piper Inventor of the Year, and NSF Presidential Young Investigator Award. His research is funded by NIH, NSF, and industry partners. Labs/Teams: Leads a lab using microfluidics and computational mechanics for vascular disease solutions. Collaborates on technologies to address post-partum hemorrhage and traumatic bleeding.
Matthew B Potts, MD is an Associate Professor in the Department of Neurological Surgery at Northwestern University's Feinberg School of Medicine, with secondary appointments in Neurology (Ken and Ruth Davee Department) and Radiology. His clinical expertise spans cerebrovascular surgery, neurointerventional/endovascular procedures, and management of brain aneurysms, vascular malformations, stroke, and spinal vascular disease across multiple Northwestern Medicine hospitals including Shirley Ryan AbilityLab. Dr. Potts completed his BS at MIT (2000) and MD at UCSF (2007), followed by surgical internship (2008), neurological surgery residency (2013), and cerebrovascular fellowship at NYU (2015). BS: Massachusetts Institute of Technology (2000) MD: University of California, San Francisco (2007) Internship: University of California-San Francisco Medical Center, Surgery (2008) Residency: University of California-San Francisco Medical Center, Neurological Surgery (2013) Fellowship: New York University Medical Center, Endovascular/Cerebrovascular Surgery (2015) His research program centers on chronic subdural hematoma pathophysiology, emergency stroke thrombectomy process optimization, and aneurysm treatment outcomes. He employs clinical-translational approaches to improve cerebrovascular disease management through advanced surgical techniques and rigorous outcomes assessment. Recent 2025 publications reveal strong focus on hydrocephalus diagnostics, hematoma expansion biomarkers, vertebrobasilar anatomy, and dolichoectatic aneurysm natural history. These works demonstrate multidisciplinary collaboration across neurosurgery, neurology, and radiology to advance diagnostic precision and treatment efficacy in complex cerebrovascular disorders. Dr. Potts has received exceptional recognition for medical education, including three consecutive Outstanding Teacher Awards (2019-2021) and the John X. Thomas, Jr. Best Teachers Award (2020). His research contributions are honored by the NIH Rush L. Kirschstein Award (2012) and Howard Hughes Fellowship (2005). Outstanding Teacher Award, Northwestern University Feinberg School of Medicine (2021) Outstanding Teacher Award, Northwestern University Feinberg School of Medicine (2020) John X. Thomas, Jr. Best Teachers of Feinberg Award, Northwestern University Feinberg School of Medicine (2020) Outstanding Teacher Award, Northwestern University Feinberg School of Medicine (2019) Ivan Ciric Resident Teaching Award, Northwestern University Department of Neurological Surgery (2017) Best Scientific Presentation, UCSF Department of Neurological Surgery (2013) NIH Rush L. Kirschstein National Research Service Award, National Institutes of Health (2012) UCSF School of Medicine Alumni Scholarship Award, University of California, San Francisco (2006) Howard Hughes Medical Institute Medical Student Research Fellow, Howard Hughes Medical Institute (2005) UCSF Quarterly Research Fellowship, University of California, San Francisco (2005) MIT-Germany Program Research Fellowship, Massachusetts Institute of Technology (2001) As an educator, Dr. Potts mentors medical students and residents through Feinberg's neurological surgery program, evidenced by his resident teaching award. His research is supported by institutional resources and prior NIH funding, with current industry relationships including ownership in Rhaeos, Inc. He serves as Assistant Editor for Neurosurgery and Associate Editor for Operative Neurosurgery. He operates within Northwestern's integrated neurovascular team across multiple hospital sites, collaborating with neurologists, neuroradiologists, and rehabilitation specialists to deliver comprehensive care for complex cerebrovascular conditions, with ongoing work focused on improving health equity in stroke treatment and minimally invasive surgical innovation.
Marjo Yliperttula is a Professor at the Department of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki. She serves as a supervisor in the Doctoral Programmes in Biomedicine, Drug Research, and Materials Research and Nanosciences, with expertise in biomaterials and pharmaceutical technology. Her research focuses on nanofibrillated cellulose (NFC) hydrogels for wound healing and drug delivery, extracellular vesicle (EV) engineering for therapeutic applications, and freeze-drying technologies for biomaterial preservation. Key contributions include NFC-based wound dressings that enhance platelet-rich plasma release (2024), Raman spectroscopy methods for monitoring freeze-drying-induced mutarotation (2024), and tandem chromatography techniques for high-purity EV isolation (2023). Her work bridges pharmaceutical sciences with regenerative medicine, emphasizing translational applications in chronic wound treatment and targeted drug delivery. Recent publications (2022-2025) reveal three dominant trends: (1) Optimization of NFC hydrogels for controlled drug release and tissue regeneration, (2) Advanced characterization of EV phenotypes under hypoxic conditions for improved therapeutic efficacy, and (3) Development of analytical methods (Raman spectroscopy, chromatography) to address manufacturing challenges in biopharmaceuticals. These themes reflect her group's commitment to solving critical problems in biomaterial stability, EV-based delivery, and precision wound care. Professor Yliperttula has supervised 10 doctoral theses, including recent work on NFC for skin substitutes (Elle Koivunotko), freeze-drying of hydrogels (Arto Merivaara), and mesenchymal stromal cells for wound healing (Jasmi Snirvi). She currently leads the Academy of Finland-funded GeneCellNa project (2024-2026) on gene/cell/nanotherapy for chronic diseases and a Finnish Red Cross project (2023-2024) on NFC for blood products, with cumulative project funding spanning 18 initiatives since 2005. She heads the Biopharmaceuticals Group within the Drug Research Program, fostering collaborations across pharmaceutical biosciences, materials science, and clinical medicine to advance next-generation therapeutic platforms.
Tyler Johnson, PhD, is an Associate Professor in the Department of Natural Sciences and Mathematics at Dominican University of California's School of Health and Natural Sciences. His expertise lies in Natural Products Chemistry , Bioorganic Chemistry , and Medicinal Chemistry , with a focus on biomedical applications. Johnson's research emphasizes discovering therapeutic lead compounds and molecular probes from marine and terrestrial natural products. His research team investigates chemotypes like mycothiazole , zampanolide , fijianolide , and latrunculin from Indo-Pacific marine sponges. These compounds exhibit potent cytotoxicity (IC50 1~5 nM) against cancer cell lines through mechanisms including microfilament disruption , mitochondrial complex I inhibition , and microtubule stabilization . Current work explores mycothiazole as a molecular probe for mitochondrial aging. Key publications span 2024-2002, covering topics from sponge-derived anticancer agents to inflammation modulation and environmental toxicology. Johnson's laboratory engages in large-scale natural product isolation, spectroscopic validation, and semi-synthetic medicinal chemistry to optimize therapeutic leads. His work integrates undergraduate and graduate students into interdisciplinary biomedical research.
Scott L. Diamond is the Arthur E. Humphrey Professor of Chemical and Biomolecular Engineering and Bioengineering at the University of Pennsylvania's School of Engineering and Applied Sciences. He serves as Director of the Penn Center for Molecular Discovery, Director of the Penn Biotechnology Masters Program (one of the largest in the country with over 130 students), and Associate Director of the Institute for Medicine and Engineering (IME). His laboratory is located in the Roy and Diana Vagelos Laboratories at 3340 Smith Walk, 1020 Vagelos Research Laboratories, Philadelphia, PA. Diamond's research spans multiple interconnected fields in blood biology and biotechnology. His work focuses on mechanobiology, thrombolysis, coagulation, bioadhesion, gene therapy, drug/device development, proteomics, drug discovery, systems biology, and microfluidics. His laboratory has developed numerous specialized microfluidic devices for studying blood clotting under various flow conditions, including 8-channel devices for high-throughput clotting assays, side-view devices for clot structure analysis, stenosis devices for high shear clotting assays, and impingement-post devices for studying von Willebrand factor fibers. Diamond's research group has pioneered approaches to model and predict blood function using systems biology principles. His team has developed computational models that integrate reaction-transport phenomena with platelet signaling networks to predict thrombus formation under flow. These models have enabled the development of 'virtual blood' computer simulations that can predict the effectiveness of anticoagulation drugs for individual patients, contributing significantly to personalized medicine approaches in hemostasis and thrombosis. His extensive publication record demonstrates a consistent focus on understanding the fundamental mechanisms of blood clot formation and dissolution. Recent work has emphasized microfluidic approaches for point-of-care diagnostics, patient-specific modeling of platelet function, and the development of novel therapeutic strategies for thrombotic disorders. His research bridges engineering principles with clinical hematology to address significant challenges in cardiovascular medicine. NSF National Young Investigator Award NIH FIRST Award American Heart Association Established Investigator Award AIChE Allan P. Colburn Award George Heilmeier Excellence in Research Award Elected Fellow of the Biomedical Engineering Society (BMES) Diamond has secured significant research funding, including a $2.8 million NIH grant for 'Blood Systems Biology' and a $9.5 million NIH grant for the Penn Center for Molecular Discovery. His laboratory has developed numerous microfluidic devices for blood analysis and has collaborated extensively with clinicians and industry partners. Diamond has served on advisory committees for NSF, NIH, AHA, and NASA, and has consulted extensively for industry and government. With over 180 publications and patents, his work has significantly advanced the understanding of blood clotting mechanisms and the development of diagnostic and therapeutic approaches for thrombotic disorders.
João F. Mano is a Full Professor at the Department of Chemistry, University of Aveiro, and Director of the Doctoral Program on Biotechnology. He leads the COMPASS Research Group and serves as Vice-Director at CICECO - Aveiro Institute of Materials. His academic appointments include Invited Professor at University of Lorraine (France), Visiting Professor at KAIST (South Korea), and Adjunct Professor at Ajou University (South Korea). Education: PhD in Chemistry (1996, Technical University of Lisbon); D.Sc. in Tissue Engineering, Regenerative Medicine and Stem Cells (2012, University of Minho) Research Interests focus on Biomaterials for Regenerative Medicine , integrating Nanotechnology , Microtechnology , and Biofabrication . His group develops Bioinspired Materials using polymer chemistry, Decellularized Extracellular Matrix , and 3D Bioprinting to engineer Cell Microenvironments for therapeutic applications. Recent Publications highlight advancements in Human-Derived Hydrogels , Photopolymerizable Scaffolds , Magneto-Responsive Biomaterials , and Programmable Bioinks . Trends show emphasis on Organ-on-a-Chip integration, Smart Living Materials , and Green Bioprinting methodologies. Scientific Awards include: European Research Council Advanced Grants (2015, 2020) Fellow at IUPAC, European Academy of Sciences, and American Institute of Medical and Biological Engineering ERC Proof of Concept Grants Doctor Honoris Causa from University of Lorraine and Utrecht UNESCO Chair on Biomaterials George Winter Award (European Society for Biomaterials) Supervisions & Collaborations encompass 74+ MSc, 26+ PhD students, and 40+ postdocs. He co-founded METATISSUE and CELLULARIS Biomodels , and serves as Editor-in-Chief of Materials Today Bio .
Eadric Bressel is a Professor and Head of the Department of Kinesiology and Health Science at Utah State University (USU). He holds a PhD in biomechanics from the University of Northern Colorado and earned his B.S. and M.S. in kinesiology from California State University, Fresno. Prior to joining USU in 2000, he was a postdoctoral fellow at the Auckland University of Technology's health and rehabilitation center. Education: PhD in Kinesiology (Biomechanics), University of Northern Colorado, 1999 MA in Kinesiology (Exercise Science), California State University, Fresno, 1995 BS in Kinesiology (Exercise Science), California State University, Fresno, 1994 Research Interests: Dr. Bressel focuses on biomechanical adaptations to therapeutic exercise in healthy and clinical populations. His work emphasizes spine stabilization exercises, determinants of balance, and aquatic rehabilitation strategies for conditions like osteoarthritis. Recent studies explore the efficacy of aquatic environments for improving motor learning, cognitive performance, and functional outcomes in older adults. Key Research Trends: His publications highlight the biomechanical benefits of aquatic training, including its impact on muscle function, postural control, and injury prevention. Cross-disciplinary studies integrate biomechanics with gerontology and sports medicine, addressing aging populations and athletic performance optimization. Awards: Excellence in Aquatic Physical Therapy Research Award (APTA Aquatic Section, 2016) Researcher of the Year (HPER Department, 2012) Employee of the Year (Kinesiology & Health Science Department, 2017) Top Professor Award (Mortar Board Senior Honor Society, 2004) Advising & Grants: Dr. Bressel has mentored over 40 graduate students, many of whom have contributed to studies on aquatic exercise, balance rehabilitation, and sports biomechanics. He has secured grants to investigate aquatic treadmill training for osteoarthritis, cognitive-aquatic interaction effects, and eccentric resistance protocols. Labs/Teams: His lab focuses on translational research integrating biomechanical analysis with clinical applications. Collaborations with institutions like the Auckland University of Technology and the American Physical Therapy Association highlight his commitment to bridging research and practice in aquatic therapy and sports science.
Helen Suh is a Professor at Tufts University, jointly appointed in the departments of Civil and Environmental Engineering and Community Health . As an internationally-recognized expert in air pollution health effects, she combines environmental epidemiology , exposure science , and data analytics to investigate how pollutants impact human health. Sc.D. , Harvard University (1993) M.S. , Harvard University (1990) S.B. , Massachusetts Institute of Technology (1985) Her research focuses on three areas: air pollutant impacts on cognitive performance and child development , multi-pollutant health effects , and GIS-based spatio-temporal modeling for epidemiological studies. Recent publications highlight her work on PM2.5 measurement error correction , hormonal disruptions in pregnancy , and machine learning applications in environmental health analysis. Current trends include: Advanced statistical methods for exposure assessment Multi-omics approaches to cardiometabolic health International comparative studies (e.g., Tehran, Puerto Rico) Long-term mortality analysis in Medicare populations Pollution-immune system interactions in vulnerable groups Policy-relevant modeling for air quality standards Helen Suh has served as an Associate Editor for the Journal of Exposure Science and Environmental Epidemiology and advised major U.S. and international health organizations. Her work spans over 150 publications and integrates multidisciplinary team leadership in environmental health science. Her laboratory develops large-scale data analytics tools and spatio-temporal exposure models to support population-level health research. Current projects include air pollution and aging cohorts , urban environmental noise measurement , and epigenetic responses to pollutants .
Anne-Mette Hvas is Professor and Dean at the Faculty of Health, Aarhus University, Denmark, where she leads academic and administrative initiatives in health sciences. Her role places her at the forefront of institutional strategy, research development, and interdisciplinary collaboration within clinical and translational medicine. Research Interests: Her work spans hematology, coagulation, platelet biology, neonatal hemostasis, and endocrinology. She investigates thrombotic and bleeding disorders in clinical contexts such as nephrotic syndrome, pregnancy, cancer surgery, and stroke. Her research integrates physiological, pharmacological, and clinical perspectives to improve patient outcomes. The recent publications reflect a strong focus on thrombin generation, platelet reactivity, endothelial dysfunction, and red blood cell behavior in acute and chronic conditions. These studies often involve multicenter collaborations and contribute to evidence-based practices in thromboprophylaxis, surgical safety, and stroke management. Scientific Contributions: Active research in hemostasis and thrombosis across diverse patient populations Leadership in clinical studies on anticoagulation, HIPEC, and neonatal platelet function Investigations into hormonal and cardiovascular aspects of Turner syndrome Advising and Grants: While specific advisees are not listed, her leadership in multiple funded research projects suggests mentorship of junior researchers and clinicians. She has led projects on platelet function in preterm neonates and coagulation in surgical oncology, indicating grant acquisition and team coordination capabilities. Labs and Teams: Though specific lab names are not mentioned, her work implies collaboration with clinical research teams in hematology, neonatology, oncology, and obstetrics at Aarhus University Hospital and affiliated centers.
Dr. Sarah Jones is an Associate Professor in Thrombosis and Haemostasis at Manchester Metropolitan University, serving as Deputy Director of Research for the Department of Life Sciences. She leads the Thrombosis Group and holds an honorary Reader position at the University of Manchester. Academic Affiliation: Manchester Metropolitan University Secondary Appointment: University of Manchester (Honorary Reader) Over 20 years, Dr. Jones has pioneered research on platelet signaling pathways and their role in thrombosis. Her current work focuses on platelet-endothelial crosstalk in disease states, with emphasis on in vitro thrombosis modeling to replace animal testing. This research, funded by BBSRC, NC3Rs, and BHF, addresses cardiovascular disease mechanisms and translational antithrombotic testing. Her scientific publications demonstrate expertise in platelet biology (Pim kinase signaling, SIRT1 regulation, proteoglycan interactions) and thrombosis modeling. Recent work includes placental perfusion studies for pregnancy-related cardiovascular complications. Grants & Projects: UKRI (NC3Rs) Partnership and Impact Award (2025-2026) UKRI BBSRC/NC3Rs grant for human haemostasis models (2023-2025) British Heart Foundation collaborations (2021-2025) Dr. Jones supervises PhD students (Mishaal Reyman, Poppy White, etc.) and teaches on Biomedical Science, Cellular Science, and Clinical Haematology programs. She has developed innovative endothelialised in-vitro thrombosis models that reduce animal usage in cardiovascular research.
Paula Mendes is a Professor of Advanced Materials and Nanotechnology at the University of Birmingham's School of Chemical Engineering. She leads the interdisciplinary Mendes Research Group, focusing on nanoscience, biosensors, and nanotechnology applications in healthcare. Her work bridges engineering, chemistry, and biology to address challenges in biofouling, molecular diagnostics, and medical technologies. She is affiliated with the Healthcare Technologies Institute (HTI), advancing translational research in regenerative medicine and diagnostics. Education: MSc (1997) and PhD (2002) in Chemical Engineering from the University of Porto. Postdoctoral research at the University of Birmingham and UCLA under Fraser Stoddart. Academic career at Birmingham since 2006, promoted to Professor in 2013. Research Interests: Development of electrically switchable surfaces for on-demand biosensing Nanomaterials for cancer diagnostics and molecular imprinting Anti-biofouling materials and nanoelectrocatalysts for fuel cells Integration of nanotechnology with biological systems Awards: ERC Advanced Grant (2024), IChemE Global Award (2016), Women in Tech Academic Award (2019), and over 100 published manuscripts. Advising & Grants: Supervises doctoral students in molecular diagnostics and biosensor development. Holds grants including EPSRC Leadership Fellowship and ERC Consolidator/Advanced Grants. Her group collaborates across disciplines to translate nanotechnology into clinical applications. Labs/Teams: Mendes Research Group at the University of Birmingham, part of the HTI network. Active in editorial roles for journals like Responsive Materials and ChemBioEng Reviews .
Robert T. Tranquillo serves as a Distinguished McKnight University Professor in the Department of Biomedical Engineering at the University of Minnesota's College of Science and Engineering. His research focuses on developing biologically-engineered vascular grafts, heart valves, and vein valves using tissue engineering approaches. Notably, his lab has demonstrated that their engineered material, produced by skin cells (fibroblasts), has the capacity to grow, which may transform the treatment of pediatric congenital heart defects. Tranquillo's research interests center on cardiovascular tissue engineering, particularly the development of "off-the-shelf" vascular grafts and heart valves. His lab fabricates tissue-equivalents by entrapping fibroblasts in fibrin gel and constraining cell-mediated gel compaction to create aligned fibrin structures. Using bioreactors, they stimulate cells to replace aligned fibrin with collagenous matrix, creating tubes suitable for surgical implantation. Upon decellularization, these become non-immunogenic replacements that support host recellularization and growth. His current work focuses on transcatheter heart valves and vein valves, combining engineered matrix tubes with stent technology, and conferring hemocompatibility using stem cell and small molecule strategies. A key aspect of his research investigates contact guidance—the ability of cells to sense and align with fibers—which is crucial for creating tissues with prescribed alignment. His publication record shows consistent output in top journals including Nature Communications, Science Translational Medicine, and PNAS, with recent work focusing on contact guidance mechanisms, pediatric valve conduits, and transcatheter valve development. His research demonstrates a clear trajectory from fundamental biomechanics to translational applications in cardiovascular medicine. Distinguished McKnight University Professor (prestigious University of Minnesota honor) Tranquillo has mentored over 40 PhD students and postdocs who have gone on to prominent positions in academia (professors at UCLA, Rutgers, Penn State), industry (Medtronic, Abbott, Boston Scientific), and government (NSF, NRO). His lab has received substantial research funding supporting their work on tissue-engineered cardiovascular replacements. The Tranquillo Research Group maintains an active website detailing their current projects and methodologies. The Tranquillo Research Group operates within the Department of Biomedical Engineering at the University of Minnesota, with laboratory facilities focused on tissue engineering, biomechanics, and cardiovascular device development. Their work bridges fundamental cell-matrix interactions with translational applications for cardiovascular disease treatment.
